Cosmo Pharmaceuticals N.V (C43) — Capital Reinvestment Ratio
Latest as of June 2022:
0.18x
Cosmo Pharmaceuticals N.V (C43) has a Capital Reinvestment Ratio of 0.18x as of June 2022, meaning it reinvests 0% of its operating cash flow (€6.28 Million) in capital expenditures (€1.11 Million). See Cosmo Pharmaceuticals N.V free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.18x
Capex / Operating Cash Flow
Operating Cash Flow
€6.28 Million
EUR
Capital Expenditures
€1.11 Million
EUR
Data as of
Jun 2022
Most recent filing
Cosmo Pharmaceuticals N.V Capital Reinvestment Ratio (2016–2024)
This chart tracks Cosmo Pharmaceuticals N.V's Capital Reinvestment Ratio across 6 annual periods.
Annual Capital Reinvestment Ratio for Cosmo Pharmaceuticals N.V (2016–2024)
Year-by-year Capital Reinvestment Ratio for Cosmo Pharmaceuticals N.V from 2016 to 2024. For live market cap and broader valuation context, see C43 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.03x | €162.41 Million | €5.65 Million | ▼ -92.4% |
| 2023 | 0.46x | €33.62 Million | €15.31 Million | ▲ +107.0% |
| 2022 | 0.22x | €33.23 Million | €7.31 Million | ▼ -49.4% |
| 2021 | 0.44x | €12.61 Million | €5.49 Million | ▲ +37.1% |
| 2020 | 0.32x | €12.98 Million | €4.12 Million | ▼ -62.6% |
| 2016 | 0.85x | €21.69 Million | €18.43 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow